Dyslipidaemia Management
On this page
Direct answer
Dyslipidaemia management aims to lower LDL cholesterol to a risk-based target, starting with a statin and adding ezetimibe, then a PCSK9 inhibitor, when targets are missed. In very high-risk patients, European guidance sets an LDL target below 55 mg/dL, while triglycerides above 500 mg/dL call for a fibrate to prevent pancreatitis. Correcting secondary causes such as hypothyroidism, nephrotic syndrome and uncontrolled diabetes comes before drug escalation.
What you must remember
- Statin intensity: high intensity is atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, reducing LDL by at least half; moderate intensity is atorvastatin 10 to 20 mg or rosuvastatin 5 to 10 mg.
- Ezetimibe: 10 mg daily blocks intestinal cholesterol absorption and is added when a statin alone misses the target, lowering LDL by roughly a fifth to a quarter.
- PCSK9 inhibitors: evolocumab and alirocumab are subcutaneous monoclonal antibodies; inclisiran is a small interfering RNA given twice yearly after initiation.
- Triglycerides: fenofibrate treats severe hypertriglyceridaemia above 500 mg/dL to prevent acute pancreatitis; levels above 1000 mg/dL need urgent lowering.
- Secondary causes: hypothyroidism, nephrotic syndrome, cholestatic liver disease, uncontrolled diabetes, alcohol excess, and drugs such as corticosteroids, oestrogens and some protease inhibitors.
- Statin myopathy: unexplained muscle pain or weakness needs creatine kinase measurement; stop the statin if symptoms are present with creatine kinase above ten times the upper limit of normal.
A diabetic man whose LDL stays above target
A 58-year-old man with type 2 diabetes and hypertension, already on atorvastatin 10 mg, has an LDL cholesterol of 118 mg/dL. The escalation follows a fixed sequence, starting with the statin itself.
- Check adherence and timing: Many apparent statin failures are missed doses, so adherence and timing are checked first.
- Screen for secondary causes: Thyroid function, urine protein, glycaemic control and liver enzymes are checked.
- Escalate the statin: The statin is raised to a high-intensity dose such as atorvastatin 40 mg, and the lipid profile is repeated after four to twelve weeks.
- Add ezetimibe: If LDL remains above the chosen target, ezetimibe 10 mg daily is added.
- Consider a PCSK9 inhibitor: A persisting gap in a very high-risk patient is closed with a PCSK9 inhibitor or inclisiran.
- Track triglycerides at each step: Triglycerides are recorded because a non-HDL cholesterol target is more reliable when they are high, and the Friedewald formula becomes invalid above 400 mg/dL.
In India, fixed-dose statin and ezetimibe combinations are widely available, and adherence often decides the outcome more than the choice of agent.
Where the examiner tests the target and the formula
Target and formula questions hide several traps.
- Trap: quoting one LDL target without naming the guideline. Correct: the 2018 ACC/AHA guideline used 70 mg/dL as the threshold for adding non-statin therapy in very high-risk patients, the 2026 ACC/AHA update restored LDL goals (below 55 mg/dL in very high risk), and ESC uses 55 mg/dL.
- Trap: trusting the Friedewald estimate at high triglycerides. Correct: Friedewald LDL, calculated as total cholesterol minus HDL minus triglycerides divided by five, is invalid above 400 mg/dL, so a direct LDL assay or non-HDL cholesterol is used.
- Trap: relying on LDL alone in Indian patients. Correct: many show low HDL, high triglycerides and small dense LDL, where LDL underestimates risk, and non-HDL cholesterol, total minus HDL, captures all atherogenic particles.
- Trap: choosing gemfibrozil alongside a statin. Correct: gemfibrozil increases the risk of myopathy with statins, so fenofibrate is the preferred fibrate when combined therapy is needed.
Frequently asked questions
What is the LDL target for very high-risk patients?
European guidance sets an LDL cholesterol target below 55 mg/dL for very high-risk patients, while the 2018 ACC/AHA guideline used 70 mg/dL as the threshold for adding non-statin therapy; the 2026 ACC/AHA update now also sets a goal below 55 mg/dL in very high risk. The guideline followed should be stated in the answer.
When is ezetimibe added to statin therapy?
Ezetimibe is added when LDL cholesterol remains above target on the maximally tolerated statin, or when the statin cannot be taken at high intensity. It lowers LDL by roughly a fifth to a quarter by blocking intestinal cholesterol absorption.
What triglyceride level needs treatment with a fibrate?
Triglycerides above 500 mg/dL are treated with fenofibrate, mainly to prevent acute pancreatitis. Levels above 1000 mg/dL need urgent lowering, sometimes with an insulin infusion or plasma exchange.
Why is gemfibrozil avoided with statins?
Gemfibrozil increases the risk of statin-associated myopathy and rhabdomyolysis when the two are combined. Fenofibrate is the preferred fibrate when a statin is also prescribed.